Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-25T19:59:24.307Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk for Definite Neuroleptic Malignant Syndrome

A Prospective Study in 223 Consecutive In-patients

Published online by Cambridge University Press:  02 January 2018

Haggai Hermesh ,
Dov Aizenberg ,
Abraham Weizman ,
Margo Lapidot ,
Catherina Mayor  and
Hanan Munitz
Haggai Hermesh*
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva and Sackler School of Medicine, Tel Aviv University, Israel
Dov Aizenberg
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva and Sackler School of Medicine, Tel Aviv University, Israel
Abraham Weizman
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva and Sackler School of Medicine, Tel Aviv University, Israel
Margo Lapidot
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva and Sackler School of Medicine, Tel Aviv University, Israel
Catherina Mayor
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva and Sackler School of Medicine, Tel Aviv University, Israel
Hanan Munitz
Affiliation:
Geha Psychiatric Hospital, Beilinson Medical Center, Petah Tikva and Sackler School of Medicine, Tel Aviv University, Israel
*
∗Geha Psychiatric Hospital, PO Box 102, Petah Tikva 49 100, Israel
Get access Rights & Permissions [Opens in a new window]

Abstract

The occurrence of neuroleptic malignant syndrome (NMS) was studied prospectively in two series of consecutive psychiatric in-patients (n = 223). The first group (n = 120) suffered from schizophrenia and was treated only with haloperidol. The second group (n=103) was treated with diverse neuroleptics. All patients were on a single antipsychotic agent with no anticholinergic drug as prophylaxis. The incidence of full NMS per admission and first neuroleptic exposure was 5/223 (2.2%). Patients with bipolar affective disorder and those treated with injections were significantly over-represented in the NMS group.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 161 , Issue 2 , August 1992 , pp. 254 - 257
Copyright
Copyright © 1992 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Addonizio, G., Susman, V. L. & Roth, S. D. (1986) Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry, 143, 1587–1590.Google ScholarPubMed
Delay, J., Pichot, P., Lemperiere, T., et al (1960) Un neuroleptique majeur non phenothiazinque et non reserpinque, l'haloperidol, dans le traitement des psychoses. Annates Medico Psychologique, 118, 145–152.Google Scholar
Deng, M. Z., Chen, G. Q. & Phillips, M. R. (1990) Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: A prospective study. American Journal of Psychiatry, 147, 1149–1155.Google Scholar
Keck, P. E. Jr, Pope, H. G. & McElroy, S. L. (1987) Frequency and presentation of NMS: a prospective study. American Journal of Psychiatry, 144, 1344–1346.Google Scholar
Keck, P. E. Jr, Pope, H. G. & Cohen, B. M., et al (1989) Risk factors for neuroleptic malignant syndrome. A case-control study. Archives of General Psychiatry, 46, 914–918.CrossRefGoogle ScholarPubMed
Kellam, A. M. P. (1987) The neuroleptic malignant syndrome: so-called. A survey of the world literature. British Journal of Psychiatry, 150, 752–759.CrossRefGoogle ScholarPubMed
Lazarus, A., Mann, S. C. & Carrof, S. N. (1989) The Neuroleptic Malignant Syndrome and Related Conditions. Clinical practice series no. 6. Washington, DC: American Psychiatric Press.Google Scholar
Levenson, J. L. (1985) Neuroleptic malignant syndrome. American Journal of Psychiatry, 142, 1137–1145.Google ScholarPubMed
Pope, H. G., Keck, P. E. Jr & McElroy, S. L. (1986) Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. American Journal of Psychiatry, 143, 1227–1233.Google Scholar
Shalev, A. & Munitz, H. (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatrica Scandinavica, 77, 337–347.CrossRefGoogle Scholar
Shalev, A., Hermesh, H. & Munitz, H. (1989) Mortality from neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 50, 18–25.Google ScholarPubMed
Spiess-Kiefer, C., Grohamann, R., Schmidt, L. G., et al (1988) Severe and life threatening adverse reactions to psychotropic drugs. Pharmacopsychiatry, 21, 290–292.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.